Literature DB >> 8064560

Clinical implications of genetic polymorphism in drug metabolism.

G T Tucker1.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 8064560

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN： 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  11 in total

1.  An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.

Authors:  D Marez; M Legrand; N Sabbagh; J M Lo-Guidice; P Boone; F Broly
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

Review 2.  The human drug metabolizing cytochromes P450.

Authors:  S A Wrighton; M VandenBranden; B J Ring
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

3.  Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.

Authors:  S W Ellis; G P Hayhurst; T Lightfoot; G Smith; J Harlow; K Rowland-Yeo; C Larsson; J Mahling; C K Lim; C R Wolf; M G Blackburn; M S Lennard; G T Tucker
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

4.  Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.

Authors:  G Smith; S Modi; I Pillai; L Y Lian; M J Sutcliffe; M P Pritchard; T Friedberg; G C Roberts; C R Wolf
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

5.  A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency.

Authors:  F Broly; D Marez; J M Lo Guidice; N Sabbagh; M Legrand; P Boone; U A Meyer
Journal:  Hum Genet       Date:  1995-11       Impact factor: 4.132

6.  Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

Authors:  O O Simooya; G Sijumbil; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 7.  The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development.

Authors:  D K Walker
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

8.  Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.

Authors:  Siew Hua Gan; Rusli Ismail; Wan Aasim Wan Adnan; Wan Zulmi
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects.

Authors:  M A van Agtmael; C A Van Der Graaf; T K Dien; R P Koopmans; C J van Boxtel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

10.  Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.

Authors:  S W Ellis; K Rowland; M J Ackland; E Rekka; A P Simula; M S Lennard; C R Wolf; G T Tucker
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.